Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Livmarli® (maralixibat) – New indication
March 13, 2024 - Mirum Pharmaceuticals announced the FDA approval of Livmarli (maralixibat), for the treatment of cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis (PFIC).
